Clinical Trial Update: Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating busulfan/melphalan conditioning for autologous stem cell transplant with lenalidomide maintenance in multiple myeloma has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Lenalidomide (lenalidomide)
• Melphalan (Melphalan)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED